Medical treatments for endometriosis

Minerva Ginecologica

Volumn 62, Issue 5, 2010, Pages 415-432

  Kappou, D ^a   Matalliotakis, M ^a   Matalliotakis, I ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Androgens; Aromatase inhibitors; Endometriosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; BUSERELIN; CYPROTERONE ACETATE; DANAZOL; DESOGESTREL PLUS ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; GESTRINONE; GONADORELIN; GONADORELIN ANTAGONIST; GOSERELIN; HISTRELIN; IMMUNOMODULATING AGENT; LEUPRORELIN; LUTEINIZING HORMONE; MATRIX METALLOPROTEINASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NAFARELIN; NAFARELIN ACETATE; NORETHISTERONE; PENTOXIFYLLINE; PROGESTERONE; TRIPTORELIN; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG;

ECTOPIC TISSUE; ENDOMETRIOSIS; HUMAN; LOW DRUG DOSE; PELVIS PAIN SYNDROME; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SYMPTOM; TREATMENT DURATION;

ANDROGENS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AROMATASE INHIBITORS; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIOSIS; FEMALE; GENITAL DISEASES, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOLOGIC FACTORS; PROGESTINS;

EID: 79251483504     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Matalliotakis IM, Arici A, Cakmak H, Goumenou AG, Koumantakis G, Mahutte NG. Familial aggregation of endometriosis in the Yale series. Arch Gynecol Obstet 2008;278:507-11.
2. Panidis DK, Matalliotakis IM. Subfertility associated with minimal to mild endometriosis. Main mechanisms. J Reprod Med 1998;43:1034-42.
3. Bulun SE. Endometriosis. N Engl J Med 2009;360:268-79.
4. Nothnick WB, D'Hooghe TM. Medical management of endometriosis: novel targets and approaches towards the development of future treatment regimes. Gynecol Obstet Invest 2003;55:189-98.
5. Hoshiai H, Ishikawa M, Sawatari Y, Noda K, Fukaya T. Laparoscopic evaluation of the onset and progression of endometriosis. Am J Obstet Gynecol 1993;169:714-9.
6. Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993;59:511-5.
7. Redwine DB. Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease. Fertil Steril 1991;56:628-34.
8. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006;12:179-89.
9. The Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2008;90:260-9.
10. Vercellini P, Somigliana E, Vigano P, Abbiate A, Barabara G, Crosignani P. Endometriosis: current therapies and new pharmacological developments. Drugs 2009;69:649-75.
11. Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003;21:209-22.
12. D'Hooghe TM. Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis? Curr Opin Obstet Gynecol 2003;15: 243-9.
13. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis- associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003;80:560-3. (Pubitemid 37102866)
14. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG. Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003;9:387-96.
15. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609-14.
16. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus on oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996;175:396-401. (Pubitemid 26390998)
17. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002;77:52-61.
18. Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 2000;74:24-30.
19. Italian Endometriosis Study Group. Oral contraceptive use and risk of endometriosis. Br J Obstet Gynaecol 1999;106:695-9.
20. Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P et al. Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol 2000;159:37-43.
21. Chen HF, Jeung EB, Stephenson M, Leung PC. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84:743-50. (Pubitemid 29075715)
22. Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin- releasing hormone analogues for pain associated with endometriosis.Cochrane Database Syst Rev 2000;2:CD000346.
23. Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003;4:CD001297.
24. Pierce JS, Gazvani R, Farquharson RG. Long-term use of gonadotrophin- releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year followup. Fertil Steril 2000;74:964-8.
25. Kiesel L, Schweppe KW, Sillem M, Siebzehnrubl E. Should add-back therapy for endometriosis be referred for optimal results? Br J Obstet Gynaecol 1996;103:15-7.
26. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740-5.
27. Freundl G, Godtke K, Gnoth C, Godehardt E, Kienle E. Steroidal 'addback' therapy in patients treated with GnRH agonists. Gynecol Obstet Invest 1998;45:22-30.
28. Franke HR, van de Weijer PH, Pennings TM, van der Mooren MJ. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril 2000;74:534-9.
29. Surrey ES. Add-back therapy and gonadotrophin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? A Back Consensus Working Group. Fertil Steril 1999;71:420-4.
30. Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Chochrane Database Syst Rev 2000;CD000346.
31. Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004;82:1303-8.
32. Hornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997;68:860-4.
33. Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Brit J Obstet Gynaecol 1999;106:672-7. (Pubitemid 29304389)
34. Olive D. Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 2004;3:83-9.
35. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5:12-6.
36. Batzer FR. GnRH analogs: options for endometriosis associated pain treatment. J Minim Invasive Gynecol 2006;13:539-45.
37. Pabuccu R, Onalan G, Kaya C. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/ intracytoplasmic sperm injection cycles. Fertil Steril 2007;88:832-9.
38. Luciano AA. Danazol treatment of endometriosis-associated pain. J Minim Invasive Gynecol 2006;13:523-4.
39. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001;4:CD000068
40. Matalliotakis IM, Athanassakis I, Goumenou AG, Neonaki MA, Koumantakis EE, Vassiliadis S et al. The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot. Mediators Inflamm 2001;10:75-80. (Pubitemid 32522163)
41. Matalliotakis IM, Neonaki MA, Koumantaki YG, Goumenou AG, Kyriakou DS, Koumantakis EE. A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. Obstet Gynecol 2000;95(6 Pt 1):810-3.
42. Cobellis L, Razzi S, Fava A, Severi FM, Igarashi M, Petraglia F. A danazol- loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril 2004;82:239-40.
43. Fedele L, Bianchi S, Viezzoli T, Arcaini L, Candiani GB. Gestrinone versus danazol in the treatment of endometriosis. Fertil Steril 1989;51:781-5.
44. Dawood MY, Obasiulu CW, Ramos J, Khan Dawood FS. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obstet Gynecol 1997;176:387-94.
45. Gestrinone Italian Study Group: Gestrinone versus a GnRHa for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Fertil Steril 1996;66:911-9.
46. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG. Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003;9:387-96.
47. Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs: a review. Am J Obstet Gynecol 2002;187:1101-6.
48. Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception. Contraception 2007;75:438-43. (Pubitemid 46766652)
49. Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med 1998;43:24-7.
50. Fedele L, Arcaini L, Bianchi S, Baglioni A, Vercellini P. Comparison of cyproterone acetate and danazol in the treatment of pelvic pain associated with endometriosis. Obstet Gynecol 1989;73:1000-4.
51. Moran C, Alcivia JC, Garcia-Hernandez E, Castro J. Treatment of endometriosis with cyproterone acetate: preliminary report. Arch Med Res 1996;27:535-8.
52. Bergqvist A, Theorell T. Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand 2001;80:628-37. (Pubitemid 32631458)
53. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006;21:248-56
54. Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001;75:485-8.
55. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis:a pilot study. Fertil Steril 2003;80:305-9.
56. Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis:a pilot study. Fertil Steril 1999;72:505-8.
57. Noble LS, Takayama K, Zeitoun KM, Putman JM, Johns DA, Hinshelwood MM et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82:600-6. (Pubitemid 27068636)
58. Dargenio R, Corbucci MG, Lamanna MA, Garcea N. Indomethacin and fertility in experimental endometriosis. Acta Eur Fertil 1992;23:85-8.
59. Hayes EC, Rock JA. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002;57:768-80.
60. Cobellis L, Razzi S, De Simone S, Sartini A, Fava A, Danero S et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;116:100-2.
61. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005;83:171-81. (Pubitemid 40094797)
62. Hull ML, Prentice A, Wang DY, Butt RP, Phillips SC, Smith SK etal. Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod 2005;20:350-8.
63. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib:cumulative meta-analysis. Lancet 2004;364:2021-9.
64. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biol 2003;83:149-55.
65. Attar E, Bulun SE. Aromatase inhibitors:the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307-18.
66. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease:from bench to treatment. Pharmacol Rev 2005;57:359-83.
67. Brandenberger AW, Lebovic DI, Tee MK, Ryan IP, Tseng JF, Jaffe RB et al. Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrium and endometriosis-derived stromal cells. Mol Hum Reprod 1999;5:651-5.
68. Yano S, Ikegami Y, Nakao K. Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittel Forschung 1996;46:192-5. (Pubitemid 26078239)
69. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR, Bulun SE. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998;69:709-13.
70. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate:a pilot study. Fertil Steril 2004;81:290-6.
71. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives:a novel treatment for endometriosis. Fertil Steril 2005;84:300-4. (Pubitemid 41125248)
72. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of postsurgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis:a prospective randomized trial. Hum Reprod 2004;19:160-7.
73. Buelke SJ, Bryant HU, Francis PC. The selective estrogen receptor modulator, raloxifene:an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol 1998;12:217-21.
74. Harris HA, Bruner-Tran KL, Zhang X, Osteen KG, Lyttle CR. A selective estrogen receptor-beta-agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20:936-41.
75. Sun HS, Hsiao KY, Hsu CC, Wu MH, Tsai SJ. Transactivation of steroidogenic acute regulatory protein in human endometriotic stromal cells is mediated by the prostaglandin EP2 receptor. Endocrinology 2003;144:3934-42.
76. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator decelopment and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38. (Pubitemid 40686652)
77. Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis:failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 1998;83:4474-80.
78. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E et al. Progesterone resistance in endometriosis:link to failure to metabolize estradiol. Mol Cell Endocrinol 2006;248:94-103.
79. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N. RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000;74:1014-9.
80. Jiang J, Wu RF, Wang ZH, Sun HC, Xu Z, Xiu HM. Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 2002;77:995-1000.
81. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance:a 1-year primate study. J Clin Endocrinol Metab 1996;81:1933-9.
82. Tjaden B, Galetto D, Woodruff JD, Rock JA. Time-related effects of RU486 treatment in experimentally induced endometriosis in the rat. Fertil Steril 1993;59:437-40.
83. Koide SS. Mifepristone:auxilliary therapeutic use in cancer and related disorders. J Reprod Med 1998;43:551-60.
84. Kettel LM, Murphy AA, Morales AJ, Yen SSC. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486). Am J Obstet Gynecol 1998;178:1151-6.
85. Stoeckemann K, Hegele-Hartung C, Chwalisz K. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats. Hum Reprod 1995;10:3264-71. (Pubitemid 26027277)
86. Slayden OD, Chwalisz K, Brenner RM. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod 2001;8:1562-74.
87. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometrosis. J Clin Endocrinol Metab 2000;85:2897-902. (Pubitemid 32269170)
88. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38.
89. Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C et al. A structural and in vitro characterization of asoprisnil:a selective progesterone receptor modulator. Mol Endocrinol 2007;21:1066-81.
90. Chwalisz K, Mattia-Goldberg C, Lee M, Winkel C, Schubert G, Elger W. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) Asoprisnil. Fertil Steril 2004;82:S83-4.
91. Mahutte NG, Matalliotakis IM, Goumenou AG, Koumantakis GE, Vassiliadis S, Arici A. Elevations in peritoneal fluid macrophage migration inhibitory factor are independent of the depth of invasion or stage of endometriosis. Fertil Steril 2004;82:97-101. (Pubitemid 38968784)
92. Arici A, Matalliotakis I, Goumenou A, Koumantakis G, Vassiliadis S, Selam B et al. Increased levels of interleukin-15 in the peritoneal fluid of women with endometriosis:inverse correlation with stage and depth of invasion. Hum Reprod 2003;18:429-32.
93. Koumantakis E, Matalliotakis I, Neonaki M, Froudarakis G, Georgoulias V Soluble serum interleukin-2 receptor, interleukin-6 and interleukin-1a in patients with endometriosis and in controls. Arch Gynecol Obstet 1994;255:107-12.
94. Ingelmo JM, Quereda F, Acien P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-alpha-2b in a murine model. Fertil Steril 1999;71:907-11. (Pubitemid 29206920)
95. Mohamed Ali AF, Fateen B, Ezzet al. Laparoscopic intraperitoneal injection of human interferon-2b in the treatment of pelvic endometriosis:a new modality. Obstet Gynecol 2000;95(suppl 1):S47-8.
96. Acien P, Quereda F, Campos A, Gomez-Torres MJ, Velasco I, Gutierrez M. Use of intraperitoneal interferon alpha-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog:a randomized clinical trial. Fertil Steril 2002;78:705-11.
97. Somigliana E, Vigano P, Rossi G, Carinelli S, Vignali M, Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod 1999;14:2944-50.
98. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A. Regression of endometrial expiants in a rat model of endometriosis treated with immune modulators loxoribine and levamisole. Fertil Steril 2000;72:135-41.
99. Matalliotakis I, Neonaki M, Zolindaki A, Hassan E, Georgoulias V, Koumantakis E. Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Int J Fertil Women Med 1997;42:211-4.
100. D'Antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombininant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally induced endometriosis in rats. J Reprod Immunol 2000;48:81-98.
101. D'Hooghe TM, Nugent N, Cuneo S, Chai DC, Deer F, Debrock S et al. Recombinant human TNF binding protein (r-hTBP-1) inhibits the development of endometriosis in baboons:a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2001;76;O-2, S-1.
102. Barrier BF, Bates GW, Leland MM, Leach DA, Robinson RD, Propst AM. Efficacy of antitumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril 2004;81:775-9.
103. Braun DP, Ding J, Dmowski WP. Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-alpha in women with endometriosis. Fertil Steril 2002;78:727-32.
104. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti- TNF-alpha treatment for deep endometriosis-associated paima randomized placebo-controlled trial. Hum Reprod 2008;23:2017-23.
105. Steinleitner A, Lambert H, Roy S. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model:a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil Steril 1991;55:26-31.
106. Nothnick WB, Curry TE, Vernon MW. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol 1994;31:151-62.
107. Balasch J, Creus M, Fabregues F, Carmona F, Martínez-Román S, Manau D. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis:a pilot randomized clinical trial. Hum Reprod 1997;12:2046-50.
108. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG. Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J Clin Invest 1997;99:2851-7.
109. Sillem M, Prifti S, Koch A, Neher M, Jauckus J, Runnebaum B. Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis. Eur J Obstet Gynecol Reprod Biol 2001;95:167-74. (Pubitemid 32297710)
110. Nap AW, Dunselman GA, de Goeij AF, Evers JL, Groothuis PGl. Inhibiting MMP activity prevents the development of endometriosis in the chicken chorioallantoic membrane model. Hum Reprod 2004;19:2180-7.
111. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000;6:45-55. (Pubitemid 30099342)
112. Laschke MW, Elitzsch, Scheuer C, Holstein JH, Vollmar B, Menger MD. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularisation and cell proliferation. Br J Pharmacol 2006;149:137-44.
113. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM . Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005 Oct;84 Suppl. 2:1144-55.
114. Park A, Chang P, Ferin M, Xiao E, Zeitoun K et al. Inhibition of endometriosis development in Rhesus monkeys by blocking VEGF receptor:a novel treatment for endometriosis. Fertil Steril 2004;82(suppl 2):S71
115. Matalliotakis IM, Goumenou AG, Koumantakis GE, Neonaki MA, Koumantakis EE, Dionyssopoulou E et al. Serum concentrations of growth factors in women with and without endometriosis:the action of antiendometriosis medicines. Int Immunopharmacol 2003;3:81-9.